Kyntra Bio (KYNB) Net Income (2014 - 2026)
Kyntra Bio (KYNB) posted Net Income of -$66000.0 for Q1 2026, down 116.92% sequentially from $390000.0 in Q4 2025, and down 100.31% YoY from $21.4 million in Q1 2025.
Kyntra Bio (KYNB) Net Income (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Net Income for 13 years, with the latest figure at -$66000.0 in Q1 2026.
- Quarterly Net Income fell 100.31% year-over-year to -$66000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $220.2 million (up 98.7% YoY) and the FY2025 annual result came in at $241.7 million, up 129.02% from the prior year.
- Net Income retreated to -$66000.0 in Q1 2026 per KYNB's latest filing, from $390000.0 in the prior quarter.
- Over five years, Net Income peaked at $213.8 million in Q3 2025 and troughed at -$92.9 million in Q4 2023.
- A 5-year average of -$15.9 million and a median of -$66000.0 in 2026 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2025: Net Income plunged 286.14% in 2022, then surged 585.02% in 2025.
- Over 5 years, Net Income stood at -$66.5 million in 2022, then sank by 39.86% to -$92.9 million in 2023, then soared by 128.67% to $26.6 million in 2024, then plunged by 98.54% to $390000.0 in 2025, then tumbled by 116.92% to -$66000.0 in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$66000.0, $390000.0, and $213.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | 11.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66,000.00 |
| Dec 31, 2025 | 390,000.00 |
| Sep 30, 2025 | 213.78 Mn |
| Jun 30, 2025 | 6.08 Mn |
| Mar 31, 2025 | 21.41 Mn |
| Dec 31, 2024 | 26.65 Mn |
| Sep 30, 2024 | 31.21 Mn |
| Jun 30, 2024 | 31.55 Mn |
| Mar 31, 2024 | 16.11 Mn |
| Dec 31, 2023 | -92.95 Mn |
| Sep 30, 2023 | -64.29 Mn |
| Jun 30, 2023 | -88.23 Mn |
| Mar 31, 2023 | -77.50 Mn |
| Dec 31, 2022 | -66.46 Mn |
| Sep 30, 2022 | -92.06 Mn |
| Jun 30, 2022 | -73.19 Mn |
| Mar 31, 2022 | -63.53 Mn |
| Dec 31, 2021 | -134.42 Mn |
| Sep 30, 2021 | 49.46 Mn |
| Jun 30, 2021 | -134.55 Mn |